Takeaways: Slenyto gives Canadian clinicians a prescription, extended‑release melatonin specifically studied for children and teens (ages 2 to <18) with autism spectrum disorder and/or Smith‑Mageni...
Browsing Tag: open label study
Takeaways: Slenyto gives Canadian clinicians a prescription, extended‑release melatonin specifically studied for children and teens (ages 2 to <18) with autism spectrum disorder and/or Smith‑Mageni...